Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | IL1RN | P18510 | 1/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59151 | 0.78 | KEAP1 (0.64) | KEAP1CA2CA1IL1RNERAP1 | |
| SCHEMBL6005110 | 0.78 | CA2 (0.64) | KEAP1CA2CA1IL1RNERAP1 | |
| SCHEMBL21033855 | 0.77 | CA1 (0.52) | CA2CA1KMT2APKMMEN1 | |
| SCHEMBL23141160 | 0.76 | KEAP1 (0.61) | KEAP1CA2CA1IL1RNERAP1 | |
| SCHEMBL28645206 | 0.75 | CA1 (0.61) | CA2CA1KMT2APKMMEN1 | |
| SCHEMBL21033856 | 0.75 | CA1 (0.61) | CA2CA1KMT2AMEN1ALDH1A1 | |
| SCHEMBL15549491 | 0.75 | CA1 (0.61) | CA2CA1KMT2AMEN1ALDH1A1 | |
| SCHEMBL6232580 | 0.75 | PTPN11 (0.34) | KEAP1CA2CA1IL1RNERAP1 | |
| Phenylsulfamide SCHEMBL253104 | 0.74 | CA1 (1.00) | KEAP1CA2CA1IL1RNERAP1 | |
| SCHEMBL593259 | 0.74 | KEAP1 (0.58) | KEAP1CA2CA1IL1RNERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235048-A1 | MEDIA LUBRICANTS SYNTHESIS WITH CLICK CHEMISTRY | WESTERN DIGITAL TECHNOLOGIES, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250346825-A1 | MEDIA LUBRICANTS SYNTHESIS WITH CLICK CHEMISTRY | WESTERN DIGITAL TECH INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-3715342-B1 | FLUOROSULFONYL-CONTAINING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHONGHONGXIN INVEST HOLDINGS SHENZHEN CO LTD (CN) | 2024-08-07 | — | — | EP | disclosed |
| US-11091442-B2 | Fluorosulfonyl-containing compound, intermediate thereof, preparation method therefor and use thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-08-17 | — | — | US | disclosed |
| US-11046653-B2 | — | — | 2021-06-29 | — | — | US | disclosed |
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-04-29 | — | — | US | disclosed |
| EP-3810612-A1 | OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2021-04-28 | — | — | EP | disclosed |
| US-20200369619-A1 | FLUOROSULFONYL-CONTAINING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-26 | — | — | US | disclosed |
| EP-3715342-A1 | FLUOROSULFONYL-CONTAINING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2020-09-30 | — | — | EP | disclosed |
| WO-2019243530-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| CN-110590609-A | Fluorine-containing sulfonyl compound, intermediate, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2019-12-20 | — | — | CN | disclosed |
| WO-2019101132-A1 | FLUOROSULFONYL-CONTAINING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海有机化学研究所 | 2019-05-31 | — | — | WO | disclosed |
| CN-104969406-A | Electrolyte solution for electrochemical device and electrochemical device | WAKO PURE CHEM IND LTD | 2015-10-07 | — | — | CN | disclosed |
| EP-2207541-B1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8518998-B2 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2207541-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | Sanofi-Aventis Deutschland GmbH (DE) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009043495-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-09 | — | — | WO | disclosed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | disclosed |
| US-4404402-A | PLANT GROWTH REGULATING NITROANILINES | AMERICAN CYANAMID COMPANY (US) | 1983-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | KEAP1 813/4885CA2 2877/4885CA1 1780/4885 |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SCN1A, SCN2A, CACNA1A | KEAP1 2645/4885CA2 394/4885CA1 2229/4885 |
| US-11046653-B2 | — | CYP4F11, NOTUM, CYP2F1 | KEAP1 245/4885CA2 1479/4885CA1 1052/4885 |
| US-20200369619-A1 | FLUOROSULFONYL-CONTAINING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, NOTUM, WEE2 | KEAP1 169/4885CA2 2685/4885CA1 1348/4885 |
| US-11091442-B2 | Fluorosulfonyl-containing compound, intermediate thereof, preparation method therefor and use thereof | WEE1, NOTUM, WEE2 | KEAP1 169/4885CA2 2685/4885CA1 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.